Bioceltix S.A. (WSE:BCX)

Poland flag Poland · Delayed Price · Currency is PLN
112.00
-4.40 (-3.78%)
Apr 24, 2025, 11:45 AM CET
61.62%
Market Cap 573.21M
Revenue (ttm) n/a
Net Income (ttm) -15.65M
Shares Out 4.92M
EPS (ttm) -3.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,078
Average Volume 11,565
Open 116.80
Previous Close 116.40
Day's Range 111.20 - 116.80
52-Week Range 58.90 - 123.00
Beta 1.55
RSI 58.22
Earnings Date Apr 25, 2025

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 28
Stock Exchange Warsaw Stock Exchange
Ticker Symbol BCX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.